Meeting
2019 ASCO Annual Meeting
Phase 2 trial of first-line pembrolizumab with platinum doublet chemotherapy and radiotherapy in patients (pts) with unresectable, locally advanced stage III non–small-cell lung cancer (NSCLC): KEYNOTE-799.
Authors
Salma K. Jabbour
Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey; Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ
Salma K. Jabbour , Keunchil Park , Dosinda Cohn , Hong Liu , Steven M. Keller , Dariusz M. Kowalski
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03631784
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS8575)
DOI
10.1200/JCO.2019.37.15_suppl.TPS8575
Abstract #
TPS8575
Poster Bd #
328a
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Two-year update from KEYNOTE-799: Pembrolizumab plus concurrent chemoradiation therapy (cCRT) for unresectable, locally advanced, stage III NSCLC.
First Author: Martin Reck
Poster
2019 ASCO Annual Meeting
Randomized, double-blind, phase 3 trial of first-line pembrolizumab + platinum doublet chemotherapy (chemo) ± lenvatinib in patients (pts) with metastatic nonsquamous non–small-cell lung cancer (NSCLC): LEAP-006.
First Author: Rina Hui
Poster
2022 ASCO Annual Meeting
EVOKE-02: A phase 2 study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) with or without platinum chemotherapy in first-line metastatic non–small cell lung cancer (NSCLC).
First Author: Edward B. Garon
Poster
2022 ASCO Annual Meeting
A randomized, double-blind, phase 3 trial of MK-7684A plus chemotherapy versus pembrolizumab plus chemotherapy as first-line therapy for metastatic non–small cell lung cancer (NSCLC): KeyVibe-007.
First Author: Marina Chiara Garassino